Drug Trials Snapshot: RHAPSIDO - RHAPSIDO (remibrutinib)

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-rhapsido RHAPSIDO is a kinase inhibitor that is approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1-antihistamine treatment.